| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PARIS—Since summer, sanofi-aventis has been trying to convince the leaders of Cambridge, Mass.-based Genzyme that $69 per share—or about $18.5 billion—is a fair price for it to be acquired by the French Big Pharma company. So far, Genzyme hasn't budged on its position that the price lowballs its true value to sanofi, and so the French pharma took things hostile Oct. 7.

The offer remains the same at $69 per share, but now sanofi is taking the tender offer straight to the shareholders, and has placed a Dec. 10, 2010 deadline for Geznyme to accept or decline the offer. Continuing with the stance it has held since the whole process began in summer, Genzyme again rejected the bid as being too low.

"The offer price does not adequately compensate Genzyme's shareholders for the strategic importance and financial benefit to sanofi-aventis of a potential transaction with Genzyme," the Cambridge-based company said in a statement.

In negotiations thus far between the two parties, a price range of $69 to $80 per share has been bandied about, but sanofi has been unwilling to move from the low end of that spectrum, saying that it needs more detailed information about Genzyme to justify raising its price, particularly since there are no rival bidders with which to compete.

Some unnamed sources have told media outlets that GlaxoSmithKline, Pfizer and Johnson & Johnson have all expressed interest in acquiring the company, but at least one of those companies, GSK, seems to be out of the running—unlesss it's operating in a serious cloak-and-dagger mode. Moncef Slaoui, the British pharma's head of research and development, told French newspaper Les Echos in early September, "An offer by GlaxoSmithKline for Genzyme does not make sense. It is too expensive."

We also ruminated a little about the issue at our ddn Online blog, which you can reach by clicking here, and we welcome any comments you might want to share there on the matter. In addition, we will be covering developments more in depth in our Oct. 13 ddn Online e-newsletter.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist using a digital tablet with futuristic data visualization graphics overlaying the screen, representing advanced laboratory data management and analysis

Unlocking laboratory efficiency: a complete guide to LIMS selection

Discover how to choose, implement, and optimize laboratory information management systems (LIMS) to streamline lab operations and ensure compliance.
Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue